Agarwal et al.; Eur. Pharm. Biopharm 2019; 142:83-91
Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections
Mathews et al.; Br J Ophthalmol. 2017; 101:481-486
Functional impairment of reading in patients with dry eye.
Eberwein et al.; Ophthalmic Res 2019
Semifluorinated Alkane Eye Drops in Chronic Ocular Graft-versus-Host Disease: A Prospective, Multicenter, Noninterventional Study
Agarwal et al; OcularSurface 2019
Preclinical Studies Evaluating the Effect of Semifluorinated Alkanes on Ocular Surface and Tear Fluid Dynamics
Wirta et al.; Ophthalmology 2019
A Clinical Phase 2 Study to Assess Efficacy, Safety and Tolerability of CyclASol® for Treatment of Dry Eye Disease (DED)
Steven et al; JOculPharmacolTher 2015; 31:498-503
Evaporation of the tear film is heavily discussed as one core reason for dry eye disease (DED). Subsequently, new artificial tear products are developed that specifically target this pathomechanism. [...]
Steven et al.; JOculPharmacolTher 2017; 33:678-685
Purpose: Meibomian gland disease is generally accepted as the leading cause for evaporative dry eye disease (DED). In a previous study, perfluorohexyloctane, a semifluorinated alkane, has been [...]
Gehlsen et al.; GraefesArchClinExpOphal 2017; 255:767-775
Purpose Cyclosporine A (Cs) has been used as effective topical therapy for inflammatory dry eye disease since more than a decade. However, due to its lipophilic character, Cs is formulated as [...]
De Majumdar et al.; CurrMolMed 2017; 17:211-220
Corticosteroids remain the mainstay therapy for uveitis, a major cause of blindness in the working age population. However, a substantial number of patients cannot benefit from the therapy due to [...]